The EIC is Europe's flagship innovation programme to identify, develop and scale up breakthrough technologies and game changing innovations.The funding and support is organised into three main funding schemes and with its Pathfinder programme the EIC supports the exploration of bold ideas for radically new technologies. It welcomes the high-risk / high gain and interdisciplinary cutting-edge science collaborations that underpin technological breakthroughs. 

Applicants participating in EIC Pathfinder projects are typically visionary scientists and entrepreneurial researchers from universities, research organisations, start-ups, high-tech SMEs or industrial stakeholders interested in technological research and innovation.

EIC establish a portfolio of projects that explore different perspectives, competing approaches or complementary aspects of the Challenge, and one of the EIC Pathfinder challenge is Cardiogenoic 

Cardiogenomics holds the potential to address existing gaps in the diagnosis and treatment of cardiovascular diseases (CVD), which would enable better outcome for the patient. Advanced genetic testing taking into account complex inheritance, or combining genetic testing, transcriptomics, proteomics and metabolomics analysis with clinical phenotype can improve clinical management of the CVD and identify more accurately, who is likely to be at risk for major cardiovascular events such as heart failure or sudden death.

The overall aim of this Challenge is to pave the way for novel therapies for major CVD conditions including haemorrhagic and ischemic stroke, aneurysm, cardiomyopathy and certain types of arrhythmias and other conditions, for which no effective treatments are currently available.

The following specific objectives have been identified:

• To identify single or multiple gene variants of high biological significance or other key molecules associated with the CVDs that would allow for accurate stratification of patients and guide the physician in their clinical management and monitoring of these CVDs.
• To identify novel targets based on these variants for specific CVD indication(s) that would allow for the development of first in class therapies for the same indication.
• To seek for novel technological solutions that could contribute to the development and acceleration of first in class therapies for major CVD conditions for which no effective treatments are currently available.

The EIC Pathfinder Challenges support collaborative research and innovation from consortia or proposals from single legal entities established in a Member State or an Associated Country (unless stated otherwise in the specific challenge chapter). In case of a consortium your proposal must be submitted by the coordinator on behalf of the consortium that includes at least two independent legal entities: Consortia of two entities must be comprised of independent legal entities from two different Member States or Associated Countries. Consortia of three or above entities follow standard rules i.e. they must include at least one legal entity established in a Member State and at least two other independent legal entities, each established in different Member States or Associated Countries

The legal entities may for example be universities, research organisations, SMEs, start-ups, natural persons. In the case of single beneficiary projects, mid-caps and larger companies will not be permitted.

Grants of up to 3 to 4 million euro support early stage development of future technologies (e.g. various activities at low Technology Readiness Levels 1-3), up to proof of concept. Pathfinder projects can also receive additional funding for testing the innovation potential of their research outputs.

Applicants must convincingly demonstrate that they have access to a large cohort of genomic and/or transcriptomics and/or proteomics and/or metabolomics database from CVD patients.

In case of interest please click on "m'interessa"  and we will contact you.